Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES...

Area of Science:

• Cardiovascular Medicine
• Pharmacogenetics
• Clinical Implementation Science

Background:

• CYP2C19 loss-of-function alleles increase cardiovascular risk in clopidogrel-treated patients undergoing percutaneous coronary intervention (PCI).
• Despite guidelines, clopidogrel remains common, necessitating strategies to optimize antiplatelet therapy.
• Pharmacogenetics (PGx) testing offers a potential solution for tailoring therapy.

Purpose of the Study:

• To assess the impact and feasibility of implementing PGx testing to guide antiplatelet therapy in PCI patients.
• To develop strategies for the clinical integration of PGx testing.
• To improve patient management by optimizing antiplatelet selection.

Main Methods:

• A pilot study with a prospective cohort design was conducted in Qatar.
• Point-of-care CYP2C19 genotyping was used to guide P2Y12 inhibitor selection for PCI patients.
• Prescribing patterns and gene-drug interactions were monitored.

Main Results:

• Of 376 patients tested, 283 received PGx-guided recommendations.
• Actionable CYP2C19 alleles were found in 22% of patients, leading to therapy changes.
• PGx-guided recommendations were adopted in 80% of cases, with an estimated annual cost reduction of $82.41 per ACS patient.

Conclusions:

• Real-world CYP2C19 genotyping is feasible and impactful for guiding antiplatelet therapy in acute coronary syndrome (ACS) and PCI patients.
• The findings support broader implementation of PGx testing in routine cardiovascular care.
• Optimizing antiplatelet therapy through PGx testing improves patient outcomes and reduces healthcare costs.